Journal of Comparative Effectiveness Research

Papers
(The H4-Index of Journal of Comparative Effectiveness Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)
ArticleCitations
Efficacy classification of modern therapies in multiple sclerosis77
Early mobilization in enhanced recovery after surgery pathways: current evidence and recent advancements66
The prevalence, characteristics and treatment of hemorrhoidal disease: results of an international web-based survey51
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis46
Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance39
COVID-19 complications in males and females: recent developments33
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients32
Evidence-based public policy making for medicines across countries: findings and implications for the future30
How does risdiplam compare with other treatments for Types 1–3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison22
Robot-assisted minimally invasive transforaminal lumbar interbody fusion versus open transforaminal lumbar interbody fusion: a retrospective matched-control analysis for clinical and quality-of-life o20
Patient-related barriers to some virtual healthcare services among cancer patients in the USA: a population-based study20
The use of nonrandomized evidence to estimate treatment effects in health technology assessment19
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus19
The prevalence, disease characteristics and treatment of chronic venous disease: an international web-based survey18
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-201918
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study17
What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework17
0.041950941085815